ADAPTIVE BIOTECHNOLOGIES (ADPT)
US00650F1093 - Common Stock
ChartMill assigns a Buy % Consensus number of 81% to ADPT. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 7.45. This target is 41.56% above the current price.
ADPT was analyzed by 14 analysts. The buy percentage consensus is at 81. So analysts seem to be very confident about ADPT.
In the previous month the buy percentage consensus was at a similar level.
ADPT was analyzed by 14 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-10-02 | BTIG | Maintains | Buy -> Buy |
| 2024-08-02 | JP Morgan | Maintains | Overweight -> Overweight |
| 2024-04-04 | BTIG | Maintains | Buy -> Buy |
| 2024-02-16 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2024-02-15 | JP Morgan | Maintains | Overweight -> Overweight |
| 2023-11-13 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-10-24 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-10-16 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-08 | Piper Sandler | Maintains | Overweight -> Overweight |
| 2023-08-04 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2023-05-05 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-02-16 | Morgan Stanley | Maintains | Equal-Weight |
| 2023-02-15 | Credit Suisse | Reiterate | Underperform |
| 2023-01-05 | ScotiaBank | Initiate | Sector Outperform |
| 2022-12-21 | Piper Sandler | Upgrade | Neutral -> Overweight |
| 2022-11-07 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-10-26 | Piper Sandler | Maintains | Neutral |
| 2022-08-25 | Credit Suisse | Initiate | Underperform |
| 2022-08-17 | Piper Sandler | Maintains | Neutral |
| 2022-06-03 | Piper Sandler | Initiate | Neutral |
| 2022-05-24 | Goldman Sachs | Maintains | Neutral |
| 2022-05-06 | Morgan Stanley | Maintains | Equal-Weight |
| 2022-02-16 | BTIG | Maintains | Buy |
| 2022-02-15 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-08-06 | Goldman Sachs | Maintains | Neutral |
| 2021-05-07 | Morgan Stanley | Maintains | Equal-Weight |
| 2021-03-03 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2021-02-26 | Morgan Stanley | Maintains | Equal-Weight |